Tarix will have an exclusive worldwide license to Unigene's Peptelligence technology for use with Angiotensin (1-7), the pharmaceutical ingredient in TXA127, as well as its functional equivalents, analogs or derivatives. Unigene will receive a percentage of revenues from sales of any approved oral dose form of Angiotensin (1-7), or from any third-party sub-licensee of its Peptelligence technology with respect to Angiotensin products.
Ashleigh Palmer, Unigene's chief executive officer, said, “Our licensing agreement with Tarix is further validation of the strength of Unigene's Peptelligence platform and the tremendous value that our feasibility program offers to innovators in the therapeutic peptide field. We are very excited to extend our feasibility partnership with Tarix into a fully-fledged licensing agreement and to work with Dr. Franklin and his company's scientific team to advance the development of what we all agree is a potentially groundbreaking drug.”
Rick Franklin, M.D., Ph.D., chief executive officer of Tarix, said, “TXA127 has always been a high-value opportunity, given its potential to treat multiple therapeutic conditions. However, our ability to potentially deliver TXA127 orally will significantly enhance its transactability with prospective advanced-stage development partners and serves to greatly differentiate it from other peptide-based drugs. Based on our experience, Unigene's Peptelligence technology and feasibility program offer the potential to truly transform the therapeutic peptide market.”